Lindsay Ackerman, MD, outlines how ruxolitinib topical has transformed the clinical approach to vitiligo.
Integrating Topical JAK Inhibition Into Vitiligo Care at Fall Clinical
The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.
Lindsay Ackerman, MD, explains the importance of transparency when prescribing medications with boxed warnings.
Marc Serota, MD, discusses using ruxolitinib cream to safely maintain repigmentation, minimize steroid-related adverse effects, and enhance outcomes when combined with phototherapy.
Marc Serota, MD, outlines how ruxolitinib cream supports gradual, sustained repigmentation, highlights the significance of “islands” of early pigment return, and discusses when to escalate or combine modalities to optimize outcomes.
Marc Serota, MD, discussed upcoming systemic JAK inhibitors, the value of ruxolitinib cream and phototherapy, and a personalized multimodal approach to improve repigmentation outcomes.
Using multiple treatment modalities often achieves superior repigmentation compared with monotherapy, according to Michael Lewitt, MD.
Michael Lewitt, MD, emphasizes adherence to twice-daily application as the primary determinant of clinical success.
Michael Lewitt, MD, reassures patients that topical ruxolitinib shows minimal systemic absorption despite sharing a mechanism with oral JAK inhibitors.
Experts discuss innovative strategies for vitiligo treatment, emphasizing the role of topical Janus kinase inhibitors and effective patient communication for optimal outcomes.